GlycoNex Inc

ROCO:4168 (Taiwan)  
NT$ 26.55 (0%) Jun 14
At Loss
P/B:
2.39
Market Cap:
NT$ 2.87B ($ 88.82M)
Enterprise V:
NT$ 2.23B ($ 69.06M)
Volume:
266.00K
Avg Vol (2M):
511.20K
Trade In:
Volume:
266.00K
At Loss
Avg Vol (2M):
511.20K
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for GlycoNex Inc ( ) from 2012 to Jun 15 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. GlycoNex stock (ROCO:4168) PE ratio as of Jun 15 2024 is 0. More Details

GlycoNex Inc (ROCO:4168) PE Ratio (TTM) Chart

To

GlycoNex Inc (ROCO:4168) PE Ratio (TTM) Historical Data

Total 1220
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
GlycoNex PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-06-15 At Loss 2024-04-11 At Loss
2024-06-14 At Loss 2024-04-10 At Loss
2024-06-13 At Loss 2024-04-09 At Loss
2024-06-12 At Loss 2024-04-08 At Loss
2024-06-11 At Loss 2024-04-03 At Loss
2024-06-07 At Loss 2024-04-02 At Loss
2024-06-06 At Loss 2024-04-01 At Loss
2024-06-05 At Loss 2024-03-29 At Loss
2024-06-04 At Loss 2024-03-28 At Loss
2024-06-03 At Loss 2024-03-27 At Loss
2024-05-31 At Loss 2024-03-26 At Loss
2024-05-30 At Loss 2024-03-25 At Loss
2024-05-29 At Loss 2024-03-22 At Loss
2024-05-28 At Loss 2024-03-21 At Loss
2024-05-27 At Loss 2024-03-20 At Loss
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-06 At Loss 2024-02-28 At Loss
2024-05-03 At Loss 2024-02-27 At Loss
2024-05-02 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss

GlycoNex Inc (ROCO:4168) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
GlycoNex Inc is a Taiwan based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies which targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability and can serve as reagent with applications that include ELISA, Western blot, flow cytometry, TLC immunostaining, and IHC. The group also provides antibody research service to its academic and industrial clients. The other services provided by the firm include functional evaluation, antibody engineering, and antibody characterization.